Radiotherapy for the Primary Tumor in Patients with Metastatic Rectal Cancer
- 98 Downloads
Abstract
Patients with metastatic rectal cancer (mRC) have a poor prognosis and suffer from several symptoms like bleeding, pain, and obstruction. Radiation therapy (RT) has been used both for palliation and improvement of overall survival (OS) in potentially curable patients. However, treatment in this setting is debated and a recent literature review included only studies published before 2000. Therefore, an analysis of literature was performed including only studies published in recent years (2010–2016) to better evaluate the effect of modern RT in these patients.
The analysis of nine reviewed studies (six retrospective and three phase II) showed that RT is able to achieve pain, bleeding, and obstruction response rate of 79, 87, and 78%, respectively. Moreover, in patients receiving radio-chemo-surgical combined modality treatment, median survivals ranging between 30 and 38 months were recorded, with 5-year survival up to 55% of patients. RT was generally well tolerated with the most common reported side effect being diarrhea/proctitis.
Further studies in this field are needed to establish the best therapeutic sequences, to define the optimal RT dose and fractionation, and to evaluate the clinical results in terms of quality of life (QoL).
Keywords
Radiotherapy Rectal cancer Synchronous metastases Literature reviewNotes
Compliance with Ethics Standards
Conflict of Interest
Milly Buwenge, Lucia Giaccherini, Alessandra Guido, Alessandra Arcelli, Gabriella Macchia, Francesco Deodato, Savino Cilla, Lorenzo Fuccio, Andrea Farioli, Silvia Cammelli, and Alessio G. Morganti declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References
Papers of particular interest published recently are denoted with: • Of importance •• Of major importance
- 1.Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2012. Ann Oncol. 2012;23:1044–52.CrossRefPubMedGoogle Scholar
- 2.Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMedGoogle Scholar
- 3.Hosseinali Khani M, Påhlman L, Smedh K. Treatment strategies for patients with stage IV rectal cancer: a report from the Swedish Rectal Cancer Registry. Eur J Cancer. 2012;48:1616–23.CrossRefPubMedGoogle Scholar
- 4.• Cameron MG, Kersten C, Vistad I, Fosså S, Guren MG. Palliative pelvic radiotherapy of symptomatic incurable rectal cancer—a systematic review. Acta Oncol. 2014;53:164–73. A systematic literature review on historical results of palliative radiotherapy in symptomatic rectal cancer reporting the results of 27 studies. The results of the analysis showed the efficacy of radiotherapy in the relief of a variety of pelvic symptoms CrossRefPubMedGoogle Scholar
- 5.Pasetto LM, Rossi E, Paris MK, Lonardi S, Monfardini S. Common management of primary rectal carcinoma in patients with stage IV disease at the diagnosis. Anticancer Res. 2003;23:4999–5004.PubMedGoogle Scholar
- 6.Bae SH, Park W, Choi DH, et al. Palliative radiotherapy in patients with symptomatic pelvic mass of metastatic colorectal cancer. Radiat Oncol. 2011;6:52.CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Lin JK, Lee LK, Chen WS, et al. Concurrent chemoradiotherapy followed by metastasectomy converts to survival benefit in stage IV rectum cancer. J Gastrointest Surg. 2012;16:1888–96.CrossRefPubMedGoogle Scholar
- 8.Jung M, Holmqvist A, Sun XF, Albertsson M. A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach. Med Oncol. 2014;31:839.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Liu KT, Wan JF, Zhu J, et al. Role of pelvic radiotherapy for locally advanced rectal cancer and synchronous unresectable distant metastases. Cancer Radiother. 2016;20:805–10.CrossRefPubMedGoogle Scholar
- 10.Yoon HI, Koom WS, Kim TH, et al. Upfront systemic chemotherapy and short-course radiotherapy with delayed surgery for locally advanced rectal cancer with distant metastases: outcomes, compliance, and favorable prognostic factors. PLoS One. 2016;11(8):e0161475.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Chia D, Lu J, Zheng H, et al. Efficacy of palliative radiation therapy for symptomatic rectal cancer. Radiother Oncol. 2016;121:258–61.CrossRefPubMedGoogle Scholar
- 12.• Tyc-Szczepaniak D, Wyrwicz L, Kepka L, et al. Palliative radiotherapy and chemotherapy instead of surgery in symptomatic rectal cancer with synchronous unresectable metastases: a phase II study. Ann Oncol. 2013;24:2829–34. A prospective phase II trial showing that short-course radiotherapy followed by chemotherapy allows most patients with metastatic rectal cancer to avoid surgery, even those with a near-obstructing lesion CrossRefPubMedGoogle Scholar
- 13.• Kim KH, Shin SJ, Cho MS, et al. A phase II study of preoperative mFOLFOX6 with short-course radiotherapy in patients with locally advanced rectal cancer and liver-only metastasis. Radiother Oncol. 2016;118:369–74. A prospective phase II trial on patients with locally advanced rectal cancer and liver-only metastases. The study was based on a sandwich approach of chemotherapy, short-course radiotherapy, and chemotherapy followed by surgical resection of primary tumor and metastases in 78% of patients. The authors concluded that the regimen was safe and effective in inducing local tumor response and achieving R0 resection CrossRefPubMedGoogle Scholar
- 14.• Picardi V, Deodato F, Guido A, et al. Palliative short-course radiation therapy in rectal cancer: a phase 2 study. Int J Radiat Oncol Biol Phys. 2016;95:1184–90. A prospective phase II study on patients with obstructing rectal cancer (M0-1) treated with short-course radiotherapy. The authors reported 1-, 2-, and 3-year colostomy-free survival of 100, 71.4,, and 47.6%, respectively. They concluded that this regimen allows avoiding colostomy in a substantial proportion of patients CrossRefPubMedGoogle Scholar
- 15.Goodman KA, Milgrom SA, Herman JM, et al. American College of Radiology (ACR). ACR Appropriateness Criteria® rectal cancer: metastatic disease at presentation. Oncology (Williston Park). 2014;28:867–71.Google Scholar
- 16.Ansaloni L, Andersson RE, Bazzoli F, et al. Guidelines in the management of obstructing cancer of the left colon: consensus conference of the World Society of Emergency Surgery (WSES) and peritoneum and surgery (PnS) Society. World J Emerg Surg. 2010;28:5–29.Google Scholar
- 17.van Hooft JE, van Halsema EE, Vanbiervliet G, et al. Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy. 2014;46:990–1053.CrossRefPubMedGoogle Scholar
- 18.Stefanidis D, Brown K, Nazario H, et al. Safety and efficacy of metallic stents in the management of colorectal obstruction. JSLS. 2005;9:454–9.PubMedPubMedCentralGoogle Scholar
- 19.Fan YB, Cheng YS, Chen NW, et al. Clinical application of self-expanding metallic stent in the management of acute left-sided colo-rectal malignant obstruction. World J Gastroenterol. 2006;12:755–9.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Miyayama S, Matsui O, Kifune K, et al. Malignant colonic obstruction due to extrinsic tumor: palliative treatment with a self-expanding nitinol stent. AJR Am J Roentgenol. 2000;175:1631–7.CrossRefPubMedGoogle Scholar